{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:05:40Z","timestamp":1791140740095,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T00:00:00Z","timestamp":1385769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00105-013-2599-9","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T16:26:29Z","timestamp":1385655989000},"page":"931-945","source":"Crossref","is-referenced-by-count":18,"title":["Bull\u00f6ses Pemphigoid","Bullous pemphigoid"],"prefix":"10.1007","volume":"64","author":[{"given":"F.","family":"Schulze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kasperkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"2599_CR1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","volume":"131","author":"Bastuji-Garin","year":"2011","unstructured":"Bastuji-Garin S, Joly P, Lemordant P et al (2011) Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131:637\u2013643","journal-title":"J Invest Dermatol"},{"key":"2599_CR2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","volume":"145","author":"Bernard","year":"2009","unstructured":"Bernard P, Reguiai T, Tacr\u00e8de-Bohin E et al (2009) Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospecte, cohort study. Arch Dermatol 145:537\u2013542","journal-title":"Arch Dermatol"},{"key":"2599_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annder.2011.01.009","volume":"138","author":"Bernard","year":"2011","unstructured":"Bernard P, Bedane C, Prost C et al (2011) Bullous pemphigoid. Guidelines for the diagnosis and treatment. Ann Dermatol Venereol 138:247\u2013251","journal-title":"Ann Dermatol Venereol"},{"key":"2599_CR4","first-page":"434","volume":"7","author":"Bertram","year":"2009","unstructured":"Bertram F, Br\u00f6cker EB, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 7:434\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"key":"2599_CR5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2133.2012.10820.x","volume":"166","author":"Bl\u00f6cker","year":"2012","unstructured":"Bl\u00f6cker IM, D\u00e4hnrich C, Probst C et al (2012) Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol 166:964\u2013970","journal-title":"Br J Dermatol"},{"key":"2599_CR6","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI3335","volume":"102","author":"B\u00fcdinger","year":"1998","unstructured":"B\u00fcdinger L, Borradori L, Yee C et al (1998) Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102:2082\u20132089","journal-title":"J Clin Invest"},{"key":"2599_CR7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/08916934.2011.606452","volume":"45","author":"Czernik","year":"2012","unstructured":"Czernik A, Toosi S, Bystryn JC, Grando SA (2012) Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 45:111\u2013118","journal-title":"Autoimmunity"},{"key":"2599_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","volume":"128","author":"Di","year":"2008","unstructured":"Di Zenzo G, Thoma-Uszynski S, Fontao L et al (2008) Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 128:415\u2013426","journal-title":"Clin Immunol"},{"key":"2599_CR9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4049\/jimmunol.1100596","volume":"187","author":"Hirose","year":"2011","unstructured":"Hirose M, Recke A, Beckmann T et al (2011) Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 187:1176\u20131183","journal-title":"J Immunol"},{"key":"2599_CR10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","volume":"144","author":"Iwata","year":"2008","unstructured":"Iwata Y, Komura K, Kodera M et al (2008) Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 144:41\u201348","journal-title":"Arch Dermatol"},{"key":"2599_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J et al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321\u2013327","journal-title":"N Engl J Med"},{"key":"2599_CR12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","volume":"129","author":"Joly","year":"2009","unstructured":"Joly P, Roujeau JC, Benichou J et al (2009) A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 129:1681\u20131687","journal-title":"J Invest Dermatol"},{"key":"2599_CR13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/157016309789869065","volume":"6","author":"Kasperkiewicz","year":"2009","unstructured":"Kasperkiewicz M, Schmidt E (2009) Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 6:270\u2013280","journal-title":"Curr Drug Discov Technol"},{"key":"2599_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ et al (2011) Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 65:552\u2013558","journal-title":"J Am Acad Dermatol"},{"key":"2599_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/08916934.2011.606447","volume":"45","author":"Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Zillikens D, Schmidt E (2012) Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 45:55\u201370","journal-title":"Autoimmunity"},{"key":"2599_CR16","unstructured":"Kasperkiewicz M, Schulze F, Meier M et al (o J) Case study of bullous pemphigoid patients treated with adjuvant immunoadsorption (eingereicht)"},{"key":"2599_CR17","first-page":"CD002292","volume":"10","author":"Kirtschig","year":"2010","unstructured":"Kirtschig G, Middleton P, Bennett C et al (2010) Interventions for bullous pemphigoid. Cochrane Database Syst Rev 10:CD002292","journal-title":"Cochrane Database Syst Rev"},{"key":"2599_CR18","first-page":"927","volume":"9","author":"Kneisel","year":"2011","unstructured":"Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges 9:927\u2013947","journal-title":"J Dtsch Dermatol Ges"},{"key":"2599_CR19","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.4049\/jimmunol.136.4.1231","volume":"136","author":"Labib","year":"1986","unstructured":"Labib RS, Anhalt GJ, Patel HP et al (1986) Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 136:1231\u20131235","journal-title":"J Immunol"},{"key":"2599_CR20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/jid.2010.357","volume":"131","author":"Langan","year":"2011","unstructured":"Langan S, Groves RW, West J (2011) The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 131:631\u2013636","journal-title":"J Invest Dermatol"},{"key":"2599_CR21","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL et al (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480\u20132488","journal-title":"J Clin Invest"},{"key":"2599_CR22","first-page":"58","volume":"149","author":"Lloyd-Lavery","year":"2013","unstructured":"Lloyd-Lavery A, Chi CC, Wojnarowska F et al (2013) The associations between bullous pemphigoid and drug use: a UK case-control study. J Am Acad Dermatol 149:58\u201362","journal-title":"J Am Acad Dermatol"},{"key":"2599_CR23","first-page":"1241","volume":"Dermatol148","author":"London","year":"2012","unstructured":"London VA, Kim GH, Fairley JA, Woodley DT (2012) Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol148:1241\u20131243","journal-title":"Arch"},{"key":"2599_CR24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","volume":"161","author":"Marazza","year":"2009","unstructured":"Marazza G, Pham HC, Sch\u00e4rer L et al (2009) Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 161:861\u2013868","journal-title":"Br J Dermatol"},{"key":"2599_CR25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","volume":"16","author":"Meyersburg","year":"2012","unstructured":"Meyersburg D, Kasperkiewicz M, Schmidt E, Zillikens D (2012) Immunoadsorption in dermatology. Ther Apher Dial 16:311\u2013320","journal-title":"Ther Apher Dial"},{"key":"2599_CR26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P et al (2012) Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 66:479\u2013485","journal-title":"J Am Acad Dermatol"},{"key":"2599_CR27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm1496","volume":"13","author":"Nishie","year":"2007","unstructured":"Nishie W, Sawamura D, Goto M et al (2007) Humanization of autoantigen. Nat Med 13:378\u2013383","journal-title":"Nat Med"},{"key":"2599_CR28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EV, Zillkens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174\u2013178","journal-title":"Arch Dermatol"},{"key":"2599_CR29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","volume":"10","author":"Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D (2010) Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 10:84\u201389","journal-title":"Autoimmun Rev"},{"key":"2599_CR30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","volume":"29","author":"Schmidt","year":"2011","unstructured":"Schmidt E, della Torre R, Borradori L (2011) Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 29:427\u2013438","journal-title":"Dermatol Clin"},{"key":"2599_CR31","first-page":"399","volume":"108","author":"Schmidt","year":"2011","unstructured":"Schmidt E, Zillikens D (2011) Diagnostik und Therapie bull\u00f6ser Autoimmundermatosen. Dtsch Arztebl Int 108:399\u2013405","journal-title":"Dtsch Arztebl Int"},{"key":"2599_CR32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320\u2013332","journal-title":"Lancet"},{"key":"2599_CR33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1046\/j.1523-1747.2002.01720.x","volume":"118","author":"Sitaru","year":"2002","unstructured":"Sitaru C, Schmidt E, Peter S et al (2002) Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 118:664\u2013671","journal-title":"J Invest Dermatol"},{"key":"2599_CR34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0092-8674(81)90115-X","volume":"24","author":"Stanley","year":"1981","unstructured":"Stanley JP, Hawley-Nelson P, Yuspa SH et al (1981) Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 24:897\u2013903","journal-title":"Cell"},{"key":"2599_CR35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.det.2011.03.008","volume":"29","author":"Ujiie","year":"2011","unstructured":"Ujiie H, Nishie W, Shimizu H (2011) Pathogenesis of bullous pemphigoid. Dermatol Clin 29:439\u2013446","journal-title":"Dermatol Clin"},{"key":"2599_CR36","first-page":"492","volume":"10","author":"Beek","year":"2012","unstructured":"Beek N van, Knuth-Rehr D, Altmeyer P et al (2012) Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges 10:492\u2013499","journal-title":"J Dtsch Dermatol Ges"},{"key":"2599_CR37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-7-49","volume":"7","author":"Beek","year":"2012","unstructured":"Beek N van, Rentzsch K, Komorowski L et al (2012) Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP Mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 7:49","journal-title":"Orphanet J Rare Dis"},{"key":"2599_CR38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","volume":"167","author":"Venning","year":"2012","unstructured":"Venning VA, Taghipour K, Mohd Mustapa MF et al (2012) British Association of Dermatologist\u2019s guidelines for the management of bullous pemphigoid 2012. Br J Dermatol 167:1200\u20131214","journal-title":"Br J Dermatol"},{"key":"2599_CR39","first-page":"21","volume":"146","author":"Wieland","year":"2010","unstructured":"Wieland CN, Comfere NI, Gibson LE et al (2010) Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 146:21\u201325","journal-title":"Arch Dermatol"},{"key":"2599_CR40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/1523-1747.ep12337492","volume":"109","author":"Zillikens","year":"1997","unstructured":"Zillikens D, Rose PA, Balding SD et al (1997) Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 109:573\u2013579","journal-title":"J Invest Dermatol"},{"key":"2599_CR41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","volume":"5","author":"Zillikens","year":"2007","unstructured":"Zillikens D, Derfler K, Eming R et al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881\u2013887","journal-title":"J Dtsch Dermatol Ges"},{"key":"2599_CR42","doi-asserted-by":"crossref","unstructured":"Zillikens D (2012) Bull\u00f6se Autoimmundermatosen. In: Plewig G, Landthaler M, Burgdorf WHC et al (Hrsg) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie, 6.\u00a0Aufl. Springer, Berlin, S\u00a0777\u2013811","DOI":"10.1007\/978-3-642-24163-5_50"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2599-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-013-2599-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2599-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T13:56:34Z","timestamp":1688824594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-013-2599-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1007\/s00105-013-2599-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,30]]}}}